Skip to main content
SpringerLink
Log in

Lipoproteins and Ischemic Stroke in Diabetes

  • Chapter
  • First Online:
Lipoproteins in Diabetes Mellitus

Part of the book series: Contemporary Diabetes ((CDI))

Abstract

About one out of ten US adults have diabetes mellitus (DM), and this prevalence is estimated to significantly increase in the years to come. Dyslipidemia is highly prevalent among patients with DM and plays a key role in the development of atherosclerosis. Several pathological changes occur at the cellular level in the vascular wall that are not explained by inherent hyperglycemia. The insulin resistance characteristic of DM activates inflammation, oxidation, increased thrombotic tendency, and disturbances in the metabolism of lipoproteins such as low-density lipoproteins, triglyceride-rich lipoproteins, and lipoprotein(a). This chapter discusses the pathophysiologic role of dyslipidemia in the development of atherosclerosis and ischemic stroke in patients with DM and reviews the evidence supporting the benefits of lipid-lowering therapies for ischemic stroke risk reduction.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Centers for Disease Control and Prevention. National diabetes statistics report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2020. p. 12–5.

    Google Scholar 

  2. Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254–743.

    Article  PubMed  Google Scholar 

  3. Gorelick PB, Wong KS, Bae H-J, Pandey DK. Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier. Stroke. 2008;39(8):2396–9.

    Article  PubMed  Google Scholar 

  4. Kumar V, Abbas AK, Aster JC. Robbins and Cotran pathologic basis of disease. Elsevier Science Health Science Division; 2014.

    Google Scholar 

  5. Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. Harrison’s principles of internal medicine. 18th ed. McGraw Hill Professional; 2011.

    Google Scholar 

  6. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Banerjee C, Chimowitz MI. Stroke caused by atherosclerosis of the major intracranial arteries. Circ Res. 2017;120(3):502–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Velican C, Velican D. Atherosclerotic involvement of human intracranial arteries with special reference to intimal necrosis. Atherosclerosis. 1982;43(1):59–69.

    Article  CAS  PubMed  Google Scholar 

  9. Velican C, Anghelescu M, Velican D. Preliminary study on the natural history of cerebral atherosclerosis. Med Interne. 1981;19(2):137–45.

    CAS  PubMed  Google Scholar 

  10. Chen XY, Wong KS, Lam WWM, Zhao H-L, Ng HK. Middle cerebral artery atherosclerosis: histological comparison between plaques associated with and not associated with infarct in a postmortem study. Cerebrovasc Dis. 2008;25(1–2):74–80.

    Article  PubMed  Google Scholar 

  11. Baker AB, Iannone A. Cerebrovascular disease. I. The large arteries of the circle of Willis. Neurology. 1959;9(5):321–32.

    Article  CAS  PubMed  Google Scholar 

  12. Mathur KS, Kashyap SK, Kumar V. Correlation of the extent and severity of atherosclerosis in the coronary and cerebral arteries. Circulation. 1963;27:929–34.

    Article  CAS  PubMed  Google Scholar 

  13. Kloska A, Malinowska M, Gabig-Cimińska M, Jakóbkiewicz-Banecka J. Lipids and lipid mediators associated with the risk and pathology of ischemic stroke. Int J Mol Sci. 2020;21(10):1–26.

    Article  Google Scholar 

  14. Quispe R, Martin SS, Jones SR. Triglycerides to high-density lipoprotein-cholesterol ratio, glycemic control and cardiovascular risk in obese patients with type 2 diabetes. Curr Opin Endocrinol Diabetes Obes. 2016;23(2):150–6.

    Article  CAS  PubMed  Google Scholar 

  15. Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81.

    Article  CAS  PubMed  Google Scholar 

  16. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2020.

    Google Scholar 

  17. Khoury JC, Kleindorfer D, Alwell K, et al. Diabetes mellitus: a risk factor for ischemic stroke in a large biracial population. Stroke. 2013;44(6):1500–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Fang HJ, Zhou YH, Tian YJ, Du HY, Sun YX, Zhong LY. Effects of intensive glucose lowering in treatment of type 2 diabetes mellitus on cardiovascular outcomes: a meta-analysis of data from 58,160 patients in 13 randomized controlled trials. Int J Cardiol. 2016;218:50–8.

    Article  PubMed  Google Scholar 

  19. Shou J, Zhou L, Zhu S, Zhang X. Diabetes is an independent risk factor for stroke recurrence in stroke patients: a meta-analysis. J Stroke Cerebrovasc Dis. 2015;24(9):1961–8.

    Article  PubMed  Google Scholar 

  20. Mi D, Li Z, Gu H, et al. Stress hyperglycemia is associated with in-hospital mortality in patients with diabetes and acute ischemic stroke. CNS Neurosci Ther. 2022;28(3):372–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Lee JS, Chang PY, Zhang Y, Kizer JR, Best LG, Howard BV. Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status: the Strong Heart Study. Diabetes Care. 2017;40(4):529–37.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Beltrán Romero LM, Vallejo-Vaz AJ, Muñiz Grijalvo O. Cerebrovascular disease and statins. Front Cardiovasc Med. 2021;8(December):1–8.

    Google Scholar 

  24. Corti MC, Guralnik JM, Salive ME, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA. 1995;274(7):539–44.

    Article  CAS  PubMed  Google Scholar 

  25. Reina SA, Llabre MM, Allison MA, et al. HDL cholesterol and stroke risk: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2015;243(1):314–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Murai A, Tanaka T, Miyahara T, Kameyama M. Lipoprotein abnormalities in the pathogenesis of cerebral infarction and transient ischemic attack. Stroke. 1981;12(2):167.

    Article  CAS  PubMed  Google Scholar 

  27. Dempsey RJ, Diana AL, Moore RW. Thickness of carotid artery atherosclerotic plaque and ischemic risk. Neurosurgery. 1990;27(3):343–8.

    Article  CAS  PubMed  Google Scholar 

  28. Toth PP, Gotto AM. High-density lipoprotein. Cholesterol. 2006;285(21):295–340.

    Google Scholar 

  29. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298(3):309–16.

    Article  CAS  PubMed  Google Scholar 

  30. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299–308.

    Article  CAS  PubMed  Google Scholar 

  31. Tanne D, Koren-Morag N, Graff E, Goldbourt U. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor. Circulation. 2001;104(24):2892–7.

    Article  CAS  PubMed  Google Scholar 

  32. Patel A, Barzi F, Jamrozik K, et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004;110(17):2678–86.

    Article  CAS  PubMed  Google Scholar 

  33. Njølstad I, Arnesen E, Lund-Larsen PG. Body height, cardiovascular risk factors, and risk of stroke in middle-aged men and women. A 14-year follow-up of the Finnmark Study. Circulation. 1996;94(11):2877–82.

    Article  PubMed  Google Scholar 

  34. Lindenstrøm E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ (Clin Res ed). 1994;309(6946):11–5.

    Article  Google Scholar 

  35. Antonios N, Angiolillo DJ, Silliman S. Hypertriglyceridemia and ischemic stroke. Eur Neurol. 2008;60(6):269–78.

    Article  CAS  PubMed  Google Scholar 

  36. Bowman TS, Sesso HD, Ma J, et al. Cholesterol and the risk of ischemic stroke. Stroke. 2003;34(12):2930–4.

    Article  CAS  PubMed  Google Scholar 

  37. Sridharan R. Risk factors for ischemic stroke: a case control analysis. Neuroepidemiology. 1992;11(1):24–30.

    Article  CAS  PubMed  Google Scholar 

  38. Shahar E, Chambless LE, Rosamond WD, et al. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2003;34(3):623–31.

    Article  PubMed  Google Scholar 

  39. Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein(a) and risk of ischemic stroke. J Am Coll Cardiol. 2019;74(1):54–66.

    Article  CAS  PubMed  Google Scholar 

  40. Hachinski V, Graffagnino C, Beaudry M, et al. Lipids and stroke: a paradox resolved. Arch Neurol. 1996;53(4):303–8.

    Article  CAS  PubMed  Google Scholar 

  41. Glader CA, Stegmayr B, Boman J, et al. Chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral infarctions. Results from a nested case-control study in Northern Sweden. Stroke. 1999;30(10):2013–8.

    Article  CAS  PubMed  Google Scholar 

  42. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106(1):9–19.

    Article  CAS  PubMed  Google Scholar 

  43. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412–23.

    Article  CAS  PubMed  Google Scholar 

  44. Nave AH, Lange KS, Leonards CO, et al. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis. 2015;242(2):496–503.

    Article  CAS  PubMed  Google Scholar 

  45. Yaghi S, Elkind MSV. Lipids and cerebrovascular disease: research and practice. Stroke. 2015;46(11):3322–8.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.

    Article  CAS  PubMed  Google Scholar 

  47. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840–4.

    Article  CAS  PubMed  Google Scholar 

  48. Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation. 2000;101(19):2271–6.

    Article  CAS  PubMed  Google Scholar 

  49. Rahman S, Rahman T, Ismail AA, Rashid AR. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab. 2007;9(6):767–80.

    Article  CAS  PubMed  Google Scholar 

  50. Salinas CAA, Chapman MJ. Remnant lipoproteins: are they equal to or more atherogenic than LDL? Curr Opin Lipidol. 2020;31(3):132–9.

    Article  CAS  PubMed  Google Scholar 

  51. Bonilha I, Hajduch E, Luchiari B, Nadruz W, Le Goff W, Sposito AC. The reciprocal relationship between LDL metabolism and type 2 diabetes mellitus. Metabolites. 2021;11(12):807.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Intern Med. 2015;278(5):483–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Karasawa T, Takahashi M. Role of NLRP3 inflammasomes in atherosclerosis. J Atheroscler Thromb. 2017;24(5):443–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89(9):763–71.

    Article  CAS  PubMed  Google Scholar 

  55. Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study - implications for LDL management. J Clin Lipidol. 2007;1(6):583–92.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Holmes MV, Millwood IY, Kartsonaki C, et al. Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke. J Am Coll Cardiol. 2018;71(6):620–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Pichler G, Amigo N, Tellez-Plaza M, et al. LDL particle size and composition and incident cardiovascular disease in a South-European population: the Hortega-Liposcale Follow-up Study. Int J Cardiol. 2018;264:172–8.

    Article  CAS  PubMed  Google Scholar 

  58. Tehrani DM, Zhao Y, Blaha MJ, et al. Discordance of low-density lipoprotein and high-density lipoprotein cholesterol particle versus cholesterol concentration for the prediction of cardiovascular disease in patients with metabolic syndrome and diabetes mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol. 2016;117(12):1921–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5(2):105–13.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Berger JS, McGinn AP, Howard BV, et al. Lipid and lipoprotein biomarkers and the risk of ischemic stroke in postmenopausal women. Stroke. 2012;43(4):958–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Havel RJ, Kane JP. Introduction: structure and metabolism of plasma lipoproteins. Online Metab Mol Bases Inherit Dis. 2017:2705–16.

    Google Scholar 

  62. Aznar J, Estelles A, Breto M, Espana F. Euglobulin clot lysis induced by tissue type plasminogen activator in subjects with increased levels and different isoforms of lipoprotein (a). Thromb Res. 1993;72(5):459–65.

    Article  CAS  PubMed  Google Scholar 

  63. Chapman MJ, Huby T, Nigon F, Thillet J. Lipoprotein (a): implication in atherothrombosis. Atherosclerosis. 1994;110(Suppl):S69–75.

    Article  CAS  PubMed  Google Scholar 

  64. Milionis HJ, Winder AF, Mikhailidis DP. Lipoprotein (a) and stroke. J Clin Pathol. 2000;53(7):487–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Kronenberg F, Steinmetz A, Kostner GM, Dieplinger H. Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci. 1996;33(6):495–543.

    Article  CAS  PubMed  Google Scholar 

  66. Zeljkovic A, Vekic J, Spasojevic-Kalimanovska V, et al. LDL and HDL subclasses in acute ischemic stroke: prediction of risk and short-term mortality. Atherosclerosis. 2010;210(2):548–54.

    Article  CAS  PubMed  Google Scholar 

  67. Miyazaki A, Sakuma S, Morikawa W, et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol. 1995;15(11):1882–8.

    Article  CAS  PubMed  Google Scholar 

  68. Nicholls SJ, Nelson AJ. HDL and cardiovascular disease. Pathology. 2019;51(2):142–7.

    Article  CAS  PubMed  Google Scholar 

  69. von Eckardstein A, Widmann C. High-density lipoprotein, beta cells, and diabetes. Cardiovasc Res. 2014;103(3):384–94.

    Article  Google Scholar 

  70. Varbo A, Nordestgaard BG. Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population. Ann Neurol. 2019;85(4):550–9.

    Article  CAS  PubMed  Google Scholar 

  71. Wadstrom BN, Wulff AB, Pedersen KM, Jensen GB, Nordestgaard BG. Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study. Eur Heart J. 2022;43(34):3258–69.

    Article  CAS  PubMed  Google Scholar 

  72. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–236.

    Article  PubMed  Google Scholar 

  73. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.

    Article  Google Scholar 

  74. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–96.

    Article  CAS  PubMed  Google Scholar 

  75. Amarenco P, Bogousslavsky J, Callahan A III, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–59.

    Article  CAS  PubMed  Google Scholar 

  76. Amarenco P, Kim JS, Labreuche J, et al. A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med. 2020;382(1):9.

    Article  CAS  PubMed  Google Scholar 

  77. Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137(15):1571–82.

    Article  CAS  PubMed  Google Scholar 

  78. Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial. Circulation. 2019;140(12):992–1003.

    Article  CAS  PubMed  Google Scholar 

  79. Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941–50.

    Article  CAS  PubMed  Google Scholar 

  80. Ray KK, Colhoun HM, Szarek M, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(8):618–28.

    Article  CAS  PubMed  Google Scholar 

  81. Tanaka K, Ishikawa Y, Yokoyama M, et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke. 2008;39(7):2052–8.

    Article  CAS  PubMed  Google Scholar 

  82. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.

    Article  CAS  PubMed  Google Scholar 

  83. Bloomfield Rubins H, Davenport J, Babikian V, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 2001;103(23):2828–33.

    Article  CAS  PubMed  Google Scholar 

  84. Bezafibrate Infarction Prevention Study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000;102(1):21–7.

    Article  Google Scholar 

  85. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–61.

    Article  CAS  PubMed  Google Scholar 

  86. ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–74.

    Article  Google Scholar 

  87. AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67.

    Article  Google Scholar 

  88. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–12.

    Article  Google Scholar 

  89. Amarenco P, Goldstein LB, Szarek M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2007;38(12):3198–204.

    Article  CAS  PubMed  Google Scholar 

  90. Callahan A, Amarenco P, Goldstein LB, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol. 2011;68(10):1245–51.

    Article  PubMed  Google Scholar 

  91. Cholesterol Treatment Trialists Collaborators, Kearney PM, Blackwell L, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–25.

    Article  Google Scholar 

  92. Giugliano RP, Pedersen TR, Saver JL, et al. Stroke prevention with the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis. Stroke. 2020;51(5):1546–54.

    Article  CAS  PubMed  Google Scholar 

  93. Jukema JW, Zijlstra LE, Bhatt DL, et al. Effect of alirocumab on stroke in ODYSSEY OUTCOMES. Circulation. 2019;140(25):2054–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Jo SH, Nam H, Lee J, Park S, Lee J, Kyoung DS. Fenofibrate use is associated with lower mortality and fewer cardiovascular events in patients with diabetes: results of 10,114 patients from the Korean National Health Insurance Service Cohort. Diabetes Care. 2021;44(8):1868–76.

    Article  CAS  PubMed  Google Scholar 

  95. Kim NH, Han KH, Choi J, Lee J, Kim SG. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ. 2019;366:l5125.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Renato Quispe, Seth S. Martin & Steven R. Jones

  2. Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA

    Michael Goestch, Brigitte Kazzi, Fawzi Zghyer & Arielle Abovich

  3. Department of Neurology, Johns Hopkins Hospital, Baltimore, MD, USA

    Steven Zeiler

  4. CGH Medical Center, Sterling, IL, USA

    Peter P. Toth

  5. Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, MD, USA

    Peter P. Toth

Authors
  1. Renato Quispe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Goestch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brigitte Kazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fawzi Zghyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arielle Abovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Steven Zeiler
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Seth S. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Peter P. Toth
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Steven R. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Renato Quispe .

Editor information

Editors and Affiliations

  1. NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia

    Alicia J. Jenkins

  2. Department of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Peter P. Toth

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Quispe, R. et al. (2023). Lipoproteins and Ischemic Stroke in Diabetes. In: Jenkins, A.J., Toth, P.P. (eds) Lipoproteins in Diabetes Mellitus. Contemporary Diabetes. Humana, Cham. https://doi.org/10.1007/978-3-031-26681-2_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-26681-2_19

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-031-26680-5

  • Online ISBN: 978-3-031-26681-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation